Janux Therapeutics, Inc.
JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigenā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$15.32
Price+0.99%
$0.15
1Y
Price
Market Cap
$934.280m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-640.0%
EBITDA Margin-652.6%
Net Profit Margin-337.8%
Free Cash Flow Margin-640.0%
EBITDA Margin-652.6%
Net Profit Margin-337.8%
Free Cash Flow MarginRevenue
$21.613m
+116.1%
1y CAGR+47.2%
3y CAGR+33.9%
5y CAGREarnings
-$114.478m
-0.7%
1y CAGR-27.9%
3y CAGR-19.1%
5y CAGREPS
-$1.84
-0.5%
1y CAGR-13.5%
3y CAGR-6.8%
5y CAGRBook Value
$941.535m
$1.028b
Assets$86.690m
Liabilities$21.571m
DebtDebt to Assets
2.1%
-0.2x
Debt to EBITDAFree Cash Flow
-$78.493m
+5.8%
1y CAGR-22.3%
3y CAGR-18.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company